Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2022–2027

ColoMARK · Identification and development of novel colorectal cancer biomarkers via state-of-the-art liquid biopsy approaches

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2022-11-01 → 2027-04-30
Финансиране от ЕС
2 656 678 €
Участници
16
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Биомаркери за рак на дебелото черво се търсят чрез течни биопсии, което позволява откриване на болестта чрез анализ на кръвта. Това помага за по-ранна диагностика, по-точно проследяване на състоянието и персонализирано лечение на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Identification and development of novel colorectal cancer biomarkers via state-of-the-art liquid biopsy approaches

ColoMARK is a European research initiative pioneering liquid biopsy strategies to transform colorectal cancer (CRC) detection and management through cutting-edge molecular technologies. CRC, the third most common cancer worldwide, represents a major health burden with nearly 2 million new cases yearly. ColoMARK focuses on three key areas: predictive biomarkers for risk assessment, diagnostic biomarkers for non-invasive early detection, and prognostic biomarkers for personalised treatment and disease monitoring. ColoMARK unites leading experts in genomics, bioinformatics, molecular biology, pathology, and technology development to address this challenge. By addressing critical gaps in CRC detection and management, ColoMARK aims to enhance patient outcomes, optimise screening efficiency, and contribute to cost-effective, sustainable healthcare solutions.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinformatics, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) that will take advantage of the assets conferred by novel liquid biopsy strategies to provide complementary and comprehensive know-how on the features required to successfully fulfil the objectives of ColoMARK: 1) to foster a next generation of scientists that can address the challenges of colorectal cancer biomarker development. The network is enforced by pre-existing collaborations from COST Action TransColonCan, and enhanced by the participation of non-academic entities, who will play an essential role in the cross-sectoral and transversal training of the researchers. It is our purpose to provide a personalised training programme that builds on the knowledge offered by the participants to produce future cross-sectoral leadership and a sustainable initiative of excellent research that enhances the competitiveness of European researchers; 2) to achieve maximum impact by appropriate dissemination, patient and public engagement, and results exploitation, activities that will be embedded in the training of the researchers. Given the promising perspectives of liquid biopsy approaches for the future of cancer prevention and management, ColoMARK will constitute an opportunity to reach outstanding scientific, technological and societal impact in a field highly relevant to Horizon Europe´s priorities in cancer, therefore enhancing European competitiveness in R&I; 3) to advance in colorectal cancer understanding by producing outstanding, synergistic research. As the main scientific aim of ColoMARK, ten tailored ground-breaking research projects, only possible in the context of ColoMARK, will be undertaken for the identification and validation of better risk, prognostic and monitoring colorectal cancer biomarkers.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз